Medium-term guidance: Continue to target three-year revenue CAGR of more than 35% for 2023-2026 and Operating EBITDA margins of approximately 20% by the end of 2026. For 2025, revenues are expected to be between GBP 160 million and GBP 170 million, consistent with medium-term revenue guidance. This is expected to be second half-weighted, consistent with prior years. Operating EBITDA profitability is expected for 2025, with a low single digit GBP million Operating EBITDA profit. Guidance excludes the impact of FX fluctuations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford BioMedica: Promising Growth and Attractive Valuation Drive Buy Rating
- Oxford BioMedica Reports Robust 2024 Financial Performance and Strategic Expansion
- Briarwood Chase Increases Stake in Oxford BioMedica
- Oxford Biomedica’s Colin Bond Joins Faron Pharmaceuticals as Non-Executive Director
- Oxford Biomedica Announces Total Voting Rights